Life sciences venture firm Frazier Life Sciences announced the closing of a $1.3 billion early-stage fund to support startup creation and investing in innovative biotech companies. The fund aims to back therapeutic programs addressing significant medical needs, with a continued focus on oncology and emerging areas such as kidney disease and immune-related conditions. Despite industry-wide funding headwinds and cautious investor sentiment, Frazier remains an active and influential player in the biotech investment landscape.